Virginia Cancer Specialists announced today its participation as a leading clinical trial site in a landmark study evaluating daraxonrasib, a first‑in‑class targeted oral therapy for patients with ...

Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated biomarker data from ...

Pancreatic cancer is notoriously lethal. But new treatments mean that may be changing, and people with the disease now have ...

An international consortium of leading cancer centers and SkylineDx has put together a comprehensive data resource to characterize the genomic and transcriptomic landscape of cutaneous squamous ...

Data show promising and sustained improvements across key measures of visual function, including low luminance visual acuity and mean macular ...

Myrtelle, Inc., a clinical-stage gene therapy company selected by the FDA for the START Pilot Program and focused on ...

Drug Farm today announced ophthalmologic and central nervous system (CNS) findings from its Phase 1b study of DF-003, a first-in-class oral ALPK1 inhibitor, will be presented at the Association for ...

SYRACUSE, NY / ACCESS Newswire / May 12, 2026 / Repair Biotechnologies, Inc., a biotechnology company developing first-in-class therapies capable of rapidly regressing atherosclerotic plaque, today ...

Data show promising and sustained improvements across key measures of visual function, including low luminance visual acuity and mean macular sensitivity as measured by microperimetry.Laru-zova was ge ...

Discusses Bezisterim's Mechanism of Action and Its Potential in Addressing Parkinson's Disease Pathology May 7, 2026 2:00 PM ...

Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease May 8, 2026 12:30 PM ...

PTC Therapeutics (NASDAQ:PTCT) reported a record first quarter for product revenue and raised its 2026 revenue outlook, ...